Ah, the financial markets. A bastion of calm, rational decision-making, entirely immune to the whims of political theater. Or so one might hope. In the ever-unfolding saga of the American economy, former President Donald Trump continues to prove that his influence on market sentiment is as undeniable as it is, shall we say, unconventional. From grand pronouncements on tariffs to impromptu pharmaceutical price negotiations, the market reaction is rarely dull, often contradictory, and always ripe for a bit of observational snark.
The latest flurry of activity, as of late November 2025, paints a picture of an economy perpetually bracing for the next headline. Trump, ever the master of the dramatic reveal, has been particularly vocal on his preferred platform, Truth Social, about his economic prowess. He recently declared that his tariff policies have not only strengthened the U.S. economy and curbed inflation but also led the stock market to hit an “ALL-TIME HIGH for the 48th time in 9 months.” One must admire the precision of that count, even if the broader market indices tell a slightly more nuanced, and frankly, less enthusiastic, tale.
Tariffs: The Gift That Keeps on Giving (or Taking)
The concept of tariffs under a potential second Trump administration remains a cornerstone of his economic doctrine, and a persistent source of market jitters. The former President recently floated the idea of a $2,000 “tariff stimulus check” or “tariff dividend” for Americans, particularly those in the middle and moderate-income brackets, funded by the “hundreds of billions of dollars” supposedly flowing into the U.S. Treasury from tariffs. It’s a bold proposal, promising a financial boost while simultaneously asserting that foreign nations are footing the bill. Economists, however, have been quick to point out that tariffs are, in fact, typically paid by U.S. importers, who then pass those costs on to American consumers through higher prices.
The feasibility of such a grand payout is, unsurprisingly, met with widespread skepticism. Experts suggest the cost of these rebate checks could easily exceed the incoming tariff revenue, creating a substantial budget deficit. Moreover, the idea of injecting hundreds of billions into the economy via stimulus checks has prompted warnings from some economists about a potential resurgence of inflation, a phenomenon many Republicans previously attributed to similar pandemic-era payouts. As one analyst dryly noted, “What Congress and Trump are trying to do with stimulus, the bond market could take away instantly.”
The market’s historical reaction to Trump’s tariff pronouncements offers a stark reminder of their disruptive potential. In April 2025, a wave of new tariffs reportedly triggered a “stock market crash,” with the average applied U.S. tariff rate skyrocketing from 2.5% to an estimated 27% by April, the highest in over a century. Goldman Sachs analysts, ever the pragmatists, estimated that every five-percentage-point increase in the U.S. tariff rate could slash S&P 500 earnings per share by 1-2%. Sustained tariffs, they warned, could reduce S&P 500 EPS forecasts by 2-3% and potentially lead to a 5% decline in the index’s fair value in the near term. So, while the former President hails tariffs as economic saviors, the market tends to view them more as a particularly aggressive form of economic acupuncture.
Truth Social: The New Financial Oracle
Beyond policy proposals, Trump’s pronouncements on Truth Social have become a unique, if somewhat chaotic, source of market intelligence. His recent boasts about the stock market hitting an “ALL-TIME HIGH for the 48th time in 9 months” offer a fascinating glimpse into a personalized interpretation of market performance. While November 2025 did indeed see major indices achieve record closing levels, driven by positive corporate earnings and easing inflation concerns, the picture wasn’t quite as uniformly rosy as the “48th time” suggests. For instance, on November 21, 2025, after an initial rebound, the major indexes still posted weekly losses, with the S&P 500 down 2%, the Dow Jones Industrial Average down 1.9%, and the Nasdaq lower by 3.2%.
The US500 (a CFD tracking the S&P 500) did rise to 6599 points on November 21, gaining 0.92% from the previous session, and was up 10.55% year-over-year, having hit an all-time high of 6921.75 in October 2025. So, yes, highs were achieved. But the journey, as always, was punctuated by significant volatility, particularly around the high-flying AI sector and stocks like Nvidia. This suggests that while the market may indeed be reaching new peaks, it’s doing so with a healthy dose of trepidation, not necessarily a serene march to the 48th record. The market’s “fear gauge,” the VIX, reportedly topped the mid-40s in April 2025, reflecting “extreme investor anxiety” following tariff announcements. One might conclude the market’s relationship with Trump’s economic pronouncements is less a steady romance and more a series of dramatic, on-again, off-again engagements.
Beyond Tariffs: Micro-Interventions and Macro Headaches
Trump’s influence isn’t limited to broad trade policy. His propensity for targeted interventions also sends ripples through specific sectors. Take, for instance, his recent order for the Department of Justice to investigate the meatpacking industry over alleged “illicit collusion, price fixing, and price manipulation” driving up beef prices. This announcement immediately introduced volatility for major players like Hormel Foods Corp and Tyson Foods. Shares of Brazilian meat giant JBS, which controls a significant portion of U.S. beef processing, reportedly fell 4.6% to $12.84 on November 7, 2025, following the news. The White House specifically named JBS, Cargill, Tyson Foods, and National Beef as controlling about 85% of U.S. beef processing, making them prime targets for scrutiny.
Similarly, the pharmaceutical sector experienced its own rollercoaster ride following Trump’s announcements regarding GLP-1 weight loss drugs. His initial vow to slash prices for medications like Ozempic to a mere $150 per month, down from an approximate $1,000 list price, sent shockwaves through the market. Novo Nordisk, the maker of Ozempic and Wegovy, saw its stock fall more than 6% (or 7%) following the announcement, while Eli Lilly, producer of Zepbound, experienced a nearly 4% (or 4.3%) drop in its shares. Other companies in the space, such as Zealand Pharma and Viking Therapeutics, also posted declines.
While analysts initially viewed the $150 target as an aspirational negotiation tactic, subsequent agreements with Eli Lilly and Novo Nordisk, announced in early November 2025, set prices for semaglutide and tirzepatide at around $350 per month for Medicare and Medicaid recipients through the “TrumpRx” direct-to-consumer platform, slated for a January 2026 launch. This move, hailed as a “pivotal moment” for the obesity treatment market, aims to expand access and lower out-of-pocket costs. The market’s reaction, however, underscores the immediate and often dramatic impact of presidential pronouncements on highly sensitive industries.
The Predictable Unpredictability
The overarching theme of Trump’s impact on stock markets remains one of predictable unpredictability. His statements, often delivered via Truth Social, act as instant catalysts, capable of triggering significant intraday market swings and high trading volumes. While he consistently champions his policies as drivers of unprecedented prosperity, analysts frequently highlight the “policy uncertainty” that his ever-changing tariff regimes and ad-hoc interventions create. This uncertainty, according to Goldman Sachs, can weigh on stock valuations and increase investor risk premiums.
As November 2025 draws to a close, the major indices continue their volatile dance. On November 21, the Dow Jones Industrial Average closed up 1.1% (nearly 500 points), the S&P 500 finished 1% higher, and the Nasdaq climbed 0.9%. This rebound was partly attributed to signals from New York Fed President John Williams suggesting a potential December rate cut. Yet, despite these daily gains, all three major indexes still ended the week in the red, with the S&P 500 down 2%, the Dow down 1.9%, and the Nasdaq falling 3.2%. This dichotomy perfectly encapsulates the “Trump effect”: moments of bullish exuberance often quickly tempered by underlying anxieties and the lingering specter of policy shifts. The market, it seems, is still trying to figure out if it’s being stimulated or simply startled.
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.